Silexion Therapeutics Ltd. (SLXN) Revenue History
Annual and quarterly revenue from 2020 to present
SLXN Revenue Over Time (2020–2025)
SLXN Revenue Growth History
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
SLXN Revenue Analysis (2020–2025)
Current Revenue & Growth
As of June 23, 2026, Silexion Therapeutics Ltd. (SLXN) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
SLXN's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including SRPT (-2.2% YoY), ARWR (+14.1% YoY), and NTLA (+45.0% YoY). Compare SLXN vs SRPT →
SLXN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLXNCurrent | $0 | - | - | - | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% |
SLXN Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $11.6M | - |
| 2024 | $0 | - | $0 | - | $-12,571,000 | - |
| 2023 | $0 | - | $0 | - | $-4,681,000 | - |
| 2022 | $0 | - | $0 | - | $-3,860,000 | - |
| 2021 | $0 | - | $0 | - | $-943,933 | - |
| 2020 | $0 | - | $0 | - | $-195,860 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLXN — Frequently Asked Questions
Quick answers to the most common questions about buying SLXN stock.
Is SLXN's revenue growth accelerating or slowing?
SLXN TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SLXN's revenue history from 2020 to 2026?
Silexion Therapeutics Ltd. (SLXN) revenue history spans 2020 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SLXN's long-term revenue growth rate (CAGR)?
Silexion Therapeutics Ltd.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SLXN.
Why does SLXN's quarterly revenue fluctuate?
SLXN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Silexion Therapeutics Ltd.'s revenue data from 2020 to 2026 shows full historical quarterly detail on this page.
How is SLXN's revenue distributed by segment?
SLXN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SLXN's revenue compare to industry peers?
Silexion Therapeutics Ltd. (SLXN) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.